Patient case discussion on treating with CELMoDs

During the Multiple Myeloma Hub Steering Committee Meeting in November 2023, key opinion leaders met to discuss patient cases on treatment with Cereblon E3 ligase modulator (CELMoDs). This recorded discussion was chaired by Paul Richardson and featured Sagar Lonial, María-Victoria Mateos, Heinz Ludwig, Hermann Einsele, Morie Gertz, Elena Zamagni, and Meral Beksac.

This session opened with a presentation from Paul Richardson in which they shared the mechanism of action, latest clinical data, and applications for CELMoDs in multiple myeloma. Richardson highlighted iberdomide and mezigdomide as novel agents and discussed the latest data from trials on their use both as monotherapies and in combination.

The panel discussed differences between the two agents, the incorporation of these drugs into the myeloma treatment landscape, and optimal combination treatments. The experts concluded by discussing the incidence of secondary malignancies associated with these agents and the applications of CELMoDs in extramedullary multiple myeloma.